Excited to share our paper looking at the downstream benefits of amyloid clearance in a patient treated with Amyloid Targeting Therapy is now available! @jama.com @patch-lab-upenn.bsky.social

JAMA Neurology@jamaneurology.com · last mo.

Presented at #AAIC26 from @JAMA.com: #Amyloid clearance was most efficient in gyral crests, not sulcal depths, and correlated locally with reduced #tau #pathology and #neurodegeneration after aducanumab therapy in #AlzheimerDisease. ja.ma/3SYsxtZ

Our new paper showing agreement between PET and plasma-based temporal models of Amyloid and Tau in Alzheimer's is up online: onlinelibrary.wiley.com/doi/10.1002/.... Thanks to all those in @patch-lab-upenn.bsky.social and Penn ADRC who made this work happen!

Temporal Modeling of Amyloid and Tau Trajectories in Alzheimer's Disease Using PET and Plasma Biomarkers

Objective This study aimed to compare positron emission tomography (PET) and plasma-based temporal modeling of amyloid and tau biomarkers in Alzheimer's disease. Methods Longitudinal amyloid PET (...

onlinelibrary.wiley.com

Excited to share our new publication! Thanks to all those from @patch-lab-upenn.bsky.social, Penn ADRC, and others that made this work happen!

JAMA Neurology@jamaneurology.com · 8mo ago

Individuals with #AlzheimerDisease showing greater clinical impairment than predicted by tau burden are more likely to have copathology, including #TDP43 and #AlphaSynuclein, and experience faster decline. ja.ma/3KLq5Du